Search Results - "Roussel Robert, V."

Molecular cytogenetic characterization of five F8 complex rearrangements: utility for haemophilia A genetic counselling by Jourdy, Y., Chatron, N., Fretigny, M., Carage, M. L., Chambost, H., Claeyssens‐Donadel, S., Roussel‐Robert, V., Negrier, C., Sanlaville, D., Vinciguerra, C.

“…Background Genomic inversions are usually balanced, but unusual patterns have been described in haemophilia A (HA) patients for intron 22 (Inv22) and intron 1…”
Get full text

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients by BOREL‐DERLON, A., FEDERICI, A. B., ROUSSEL‐ROBERT, V., GOUDEMAND, J., LEE, C. A., SCHARRER, I., ROTHSCHILD, C., BERNTORP, E., HENRIET, C., TELLIER, Z., BRIDEY, F., MANNUCCI, P. M.

“…Background and objectives: A plasma‐derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat…”
Get full text

Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience by Rossi, B., Blanche, P., Roussel-Robert, V., Berezné, A., Combe, S., Coppo, P., Guillevin, L., Le Jeunne, C., Mouthon, L., Ounnoughene, N., Stieltjes, N., Groh, M.

Get full text

Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia? by Barré, A., Dréanic, J., Flaujac, C., Roussel-Robert, V., Stieltjes, N., Combe-Marzelle, S., Coriat, R., Horellou, MH

Get full text

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series by Iorio, A., Barbara, A. M., Makris, M., Fischer, K., Castaman, G., Catarino, C., Gilman, E., Kavakli, K., Lambert, T., Lassila, R., Lissitchkov, T., Mauser‐Bunschoten, E., Mingot‐Castellano, M. E., Ozdemir, N., Pabinger, I., Parra, R., Pasi, J., Peerlinck, K., Rauch, A., Roussel‐Robert, V., Serban, M., Tagliaferri, A., Windyga, J., Zanon, E.

“…Background Development of inhibitors is the most serious complication in haemophilia A treatment. The assessment of risk for inhibitor formation in new or…”
Get full text

Assessment of the budgetary impact of an emicizumab therapy introduction for patients with severe haemophilia A without inhibitor by Oka, G, Pieragostini, R, Roussel-Robert, V, Paubel, P, Degrassat-Theas, A, Lopez, I

“…Since March 2019, émicizumab is indicated for the treatment of patients with severe haemophilia A without inhibitor. This therapy's price amounts approximately…”
Get more information

Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience by Stieltjes, N., Altisent, C., Auerswald, G., Négrier, C., Pouzol, P., Reynaud, J., Roussel-Robert, V., Savidge, G. F., Villar, A., Schulman, S.

“…This retrospective, open‐label, non‐comparative study evaluated continuous infusion of recombinant factor VIII (ReFacto®), B‐domain deleted recombinant FVIII…”
Get full text

Rituximab alone or in association with corticosteroids in the treatment of acquired factor VIII inhibitors: report of two cases by Berezné, A., Stieltjes, N., Le‐Guern, V., Teixeira, L., Billy, C., Roussel‐Robert, V., Flaujac, C., Horellou, M.‐H., Guillevin, L., Mouthon, L.

“…Acquired haemophilia is a factor VIII (FVIII) deficiency due to autoantibodies directed against FVIII that can be responsible for severe haemorrhage. The…”
Get full text

Perioperative management and neuraxial analgesia in women with factor XI deficiency (<60 IU/dL): a French multicenter observational study of 314 pregnancies by Flaujac, C., Faille, D., Lavenu-Bombled, C., Drillaud, N., Lasne, D., Billoir, P., Desconclois, C., Touzet, L., Lebreton, A., Diaz-Cau, I., d’Oiron, R., Giansily-Blaizot, M., Wibaut, B., Beurrier, P., Volot, F., Rugeri, L., Roussel-Robert, V., de Raucourt, E.

“…Factor (F)XI deficiency is a rare bleeding disorder with a poor correlation between bleeding tendency and FXI level. Management of pregnant women with FXI…”
Get full text

Factor VIII inhibitors development following introduction of B‐domain‐deleted recombinant factor VIII in four hemophilia A previously treated patients by Roussel‐Robert, V., Torchet, M. F., Legrand, F., Rothschild, C., Stieltjes, N.

Get full text

Factor VIII inhibitors development following introduction of B‐domain‐deleted recombinant factor VIII in four hemophilia A previously treated patients by Roussel‐Robert, V., Torchet, M. F., Legrand, F., Rothschild, C., Stieltjes, N.

Get full text

Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and Inhibitors by d’Oiron, Roseline, Volot, F., Reynaud, J., Peerlinck, K., Goudemand, J., Guérois, C., Rothschild, C., Chambost, H., Borel-Derlon, A., Roussel-Robert, V., Marquès-Verdier, A., Lienhart, A., Berthier, A.M., Moreau, P., Lambert, T.

“…Patients with mild/moderate hemophilia A (MHA) may develop inhibitors to factor VIII (FVIII). In this condition, FVIII clotting activity (FVIII:C) baseline…”
Get full text

Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency by Alhenc-Gelas, Martine, Plu-Bureau, Genevieve, Hugon-Rodin, Justine, Picard, Véronique, Horellou, Marie-Helene

“…Inherited quantitative (type I) or qualitative (type II) antithrombin deficiency (ATD) due to mutations in the SERPINC1 gene is a well-known risk factor for…”
Get more information

OC 43.3 Surgery in People with Hemophilia a Receiving Emicizumab Prophylaxis: Real-World Experience from a Single French Reference Center of Hemophilia by Brakta, C., Stieltjes, N., Combe, S., Ounnoughene, N., Duchemin, J., Capdevila, L., Goubeau, L., Fontenay, M., Roussel Robert, V., Proulle, V.

Get full text

The Hemarthrosis-Simulating Knee Model: A Useful Tool for Individualized Education in Patients with Hemophilia (GEFACET Study) by le Doré, Sophie, Grinda, Nathalie, Ferré, Emmanuelle, Roussel-Robert, Valerie, Frotscher, Birgit, Chamouni, Pierre, Meunier, Sandrine, Bayart, Sophie, Dolimier, Edita, Truong-Berthoz, Francoise, de Raucourt, Emmanuelle

“…Hemophilic arthropathy is a major complication in patients with severe hemophilia. A plastic knee model has been developed for the therapeutic education of…”
Get full text

Traitement de l’hémophilie acquise A par rituximab : expérience d’un centre sur dix ans by Rossi, B., Groh, M., Roussel-Robert, V., Berezne, A., Mouthon, L., Le Jeunne, C., Guillevin, L., Stieltjes, N., Blanche, P.

“…L’hémophilie A acquise(HAA) est une maladie hémorragique auto-immune au pronostic sévère. L’amélioration de la prise en charge a permis une diminution du taux…”
Get full text

Extractions dentaires chez l’enfant présentant une maladie hémorragique constitutionnelle : protocole thérapeutique et résultats by Kaddour Brahim, A., Stieltjes, N., Roussel-Robert, V., Yung, F., Ginisty, D.

“…Nous rapportons les résultats de 10 ans d’expérience avec un protocole d’hémostase locale spécifiquement élaboré pour les enfants atteints de maladies…”
Get full text

Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia? by Barré, A, Dréanic, J, Flaujac, C, Roussel-Robert, V, Stieltjes, N, Combe-Marzelle, S, Coriat, R, Horellou, Mh

Get full text

Experiences of continuous infusion of B-domain deleted recombinant factor VIII (ReFacto®) for major surgery by Schulman, S, Roussel-Robert, V, Stieltjes, N, Negrier, C, Reynaud, J, Villar, A, Pouzol, P, Savidge, GF, Altisent, C, Auerswald, G

Get full text

Dental extractions in children with congenital coagulation disorders: therapeutic protocol and results by Kaddour Brahim, A, Stieltjes, N, Roussel-Robert, V, Yung, F, Ginisty, D

“…We report the results of our 10-year experience with a protocol of local hemostasis specifically elaborated for children with congenital bleeding disorders…”
Get full text